
Omeros (OMER) Stock Forecast & Price Target
Omeros (OMER) Analyst Ratings
Bulls say
Omeros is a commercial-stage biotechnology company with a strong pipeline of innovative protein and small-molecule therapeutics targeting complement-mediated diseases, cancers, and addictive or compulsive disorders. The recent launch of YARTEMLEA, the first and only approved MASP-2 inhibitor, for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA), has exceeded expectations and provided early evidence of strong institutional traction and demand. This, along with potential future milestones from the NVO partnership, leads analysts to believe in a favorable risk-reward outlook for Omeros from current levels. Additionally, the company's mechanistic differentiation and favorable safety profile compared to terminal C5 inhibitors could also drive commercial preference from transplant centers.
Bears say
Omeros is facing setbacks with their EU approval, causing them to lower their price target and remove Europe from their plans. Despite this setback, Omeros has potential with their upcoming YARTEMLEA launch and partnership with NVO, making them a viable option for investors. However, the success of AZN's ravulizumab in the same market may pose a threat to Omeros, as it could potentially change real-world transplant-center behavior after YARTEMLEA has secured approval and established experience.
This aggregate rating is based on analysts' research of Omeros and is not a guaranteed prediction by Public.com or investment advice.
Omeros (OMER) Analyst Forecast & Price Prediction
Start investing in Omeros (OMER)
Order type
Buy in
Order amount
Est. shares
0 shares